A novel noninvasive endoscopy trial lends further support for the safety of single antiplatelet therapy after a 6-month course of dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI). Results from the OPT-PEACE trial show that patients at low bleeding risk on aspirin or clopidogrel monotherapy for an additional 6 months after DAPT